SPARC has partnered with Milken Institute Finance and BrightEdge, the impact investing arm of the American Cancer Society (ACS), to design a market solution that overcomes market failures through targeted investment leveraging the unique assets of ACS.
Scientific Priorities
Our collaborative diligence identified prevention, early detection, and diagnosis as a priority market failure to address as this early phase in the patient journey has the greatest potential to save lives from cancer.Â
A Financial Innovation Lab hosted in partnership between the Milken Institute and ACS identifies mechanisms for strategically investing in this space to drive improved long-term health outcomes in individuals diagnosed with or at risk for cancer.
In partnership with the American Cancer Society and its impact investment arm, BrightEdge, SPARC and Milken Institute Catalytic Capital published a report identifying strategies to overcome barriers to investment in prevention, early detection, and diagnosis.
SPARC conducted a landscape analysis of the GBM research and funding ecosystem to highlight opportunities where philanthropy can accelerate progress and translate promising science into life-extending treatments.
SPARC analyzed the scientific and clinical landscape of uLMS to identify unmet needs and opportunities where philanthropy can drive innovation and accelerate progress.
As genetic research advances, questions remain about how this knowledge translates into better treatments and care. This panel examines successes, challenges, and future directions in using genetics to inform medicine.